Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion, inactivated) (Hualan Biological Vaccine)
- Development stage
- Approved
- Lead developer
- Hualan Biological Bacterin
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated split-virion influenza vaccine is a seasonal vaccine designed to provide active immunity against influenza A and B viruses. It is produced by growing the virus in embryonated chicken eggs, followed by inactivation (killing) and chemical disruption (splitting) of the viral particles. This splitting process reduces the reactogenicity of the vaccine while preserving the essential surface antigens, hemagglutinin (HA) and neuraminidase (NA), which are critical for inducing a protective immune response. Developed and manufactured by companies such as Hualan Biological Vaccine Co., Ltd., this vaccine is typically formulated as a trivalent or quadrivalent preparation based on annual World Health Organization (WHO) recommendations. It is administered via intramuscular injection and is widely used in public health programs to prevent influenza-related morbidity and mortality.
- Brand names
- Anflu
- Other names
- Influenza Split Virion VaccineInactivated Split Influenza VaccineInfluenza Vaccine (Split Virion), Inactivated
02
Targets
BCR (B-cell receptor specific for influenza antigens)Influenza virus internal proteinsγδ TCR (T-cell receptor)NeuraminidaseHA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (split virion, inactivated) (Hualan Biological Vaccine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion, inactivated) (Hualan Biological Vaccine).